Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCR-JAK2 fusion
i
Other names:
BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
613
;
3717
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BCR-ABL1 F317I + ABL1 F317C (1)
BCR-ABL1 F317I + ABL1 F317C + ABL1 F1317L (1)
BCR-ABL1 T315I + ABL1 E255K (1)
BCR-ABL1 T315I + ABL1 E255V (1)
BCR-ABL1 fusion + SET underexpression (1)
CRLF2 rearrangement + JAK2 fusion (1)
HMGA1 deletion+ JAK2 V617F (1)
IGH-CRLF2 fusion + JAK2 GPInsR683 (1)
IGH-CRLF2 fusion + JAK2 R867Q (1)
IGH-CRLF2 fusion + JAK2 R683G (1)
JAK2 mutation + MSI-H/dMMR (1)
P2RY8-CRLF2 fusion + JAK2 QGinsR683 (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22) (1)
HMGA1 deletion+ JAK2 V617 (0)
BCR-ABL1 F317I + ABL1 F317C (1)
BCR-ABL1 F317I + ABL1 F317C + ABL1 F1317L (1)
BCR-ABL1 T315I + ABL1 E255K (1)
BCR-ABL1 T315I + ABL1 E255V (1)
BCR-ABL1 fusion + SET underexpression (1)
CRLF2 rearrangement + JAK2 fusion (1)
HMGA1 deletion+ JAK2 V617F (1)
IGH-CRLF2 fusion + JAK2 GPInsR683 (1)
IGH-CRLF2 fusion + JAK2 R867Q (1)
IGH-CRLF2 fusion + JAK2 R683G (1)
JAK2 mutation + MSI-H/dMMR (1)
P2RY8-CRLF2 fusion + JAK2 QGinsR683 (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22) (1)
HMGA1 deletion+ JAK2 V617 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-JAK2 fusion
Acute Lymphocytic Leukemia
BCR-JAK2 fusion
Acute Lymphocytic Leukemia
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.